Testing effectiveness (Phase 2)Active Not RecruitingNCT06577025
What this trial is testing
Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 43